Intuitive Surgical posts Q3 2026 earnings beat, settles antitrust case and narrows procedure‑growth outlook

Intuitive Surgical reported third‑quarter 2026 revenue of $3.05 billion, up 22% year‑over‑year, and adjusted earnings of $3.00 per share, beating estimates. GAAP net income fell to $523 million, or $1.49 per share, after a $450 million pre‑tax charge for an antitrust settlement. The company narrowed its full‑year da Vinci procedure‑growth forecast to 14%‑15%, citing the settlement and pricing actions, and its shares fell about 7% in after‑hours trading.

The settlement charge reduced GAAP earnings and triggered a share‑price decline, affecting investors’ valuation of ISRG. The narrowed procedure‑growth outlook may temper expectations for revenue expansion in 2026, influencing analyst forecasts and investor sentiment.

  • 1Q3 2026 revenue was $3.05 billion, a 22% increase from $2.51 billion in Q3 2025.
  • 2Adjusted EPS was $3.00, up from $2.40 a year earlier.
  • 3GAAP net income was $523 million, or $1.49 per diluted share, down from $704 million and $1.95 per share in Q3 2025.
  • 4The GAAP decline reflects a $450 million pre‑tax charge for settling an antitrust class‑action litigation.
  • 5The company expects worldwide da Vinci procedures to grow 14%‑15% in 2026, narrowing the prior 13.5%‑15.5% range.
  • 6Shares fell roughly 7% in after‑hours trading following the release.

Sources